Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 14/20 | 0.43 |
| ▸ | ITGAV | P06756 | 14/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | EEF2K | O00418 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7533714 | 1.00 | ATM (0.43) | ATML3MBTL1ITGB3ITGAVALDH1A1 | |
| SCHEMBL5878670 | 0.85 | ITGB3 (0.53) | ATML3MBTL1ITGB3ITGAVALDH1A1 | |
| SCHEMBL5878678 | 0.85 | ITGB3 (0.53) | ATML3MBTL1ITGB3ITGAVALDH1A1 | |
| SCHEMBL2005489 | 0.65 | PKM (0.48) | ALDH1A1 | |
| SCHEMBL11489064 | 0.64 | ALDH1A1 (0.56) | L3MBTL1ALDH1A1 | |
| SCHEMBL2949920 | 0.63 | PKM (0.50) | ALDH1A1 | |
| SCHEMBL13136011 | 0.62 | GPR88 (0.54) | ATMALDH1A1 | |
| SCHEMBL13626320 | 0.62 | GPR88 (0.54) | ATMALDH1A1 | |
| SCHEMBL12666562 | 0.62 | GPR88 (0.52) | ALDH1A1 | |
| SCHEMBL22229267 | 0.62 | GPR88 (0.53) | ATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020016461-A1 | Biphenyl and biphenyl-analogous compounds as integrin antagonists | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016461-A1 | Biphenyl and biphenyl-analogous compounds as integrin antagonists | ITGB1, ITGB2, ITGB3 | ATM 3722/4885L3MBTL1 1149/4885ITGB3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.